FDA/CDC

Lymphoma risk prompts FDA recall of Allergan’s textured breast implants

Publish date: July 24, 2019

 

Pages

Recommended Reading

High-dose MTX-based chemo is well tolerated in older PCNSL patients
Federal Practitioner
CAR T-cell therapy bb2121 performs well in phase 1 trial of refractory multiple myeloma
Federal Practitioner
Lenalidomide may reduce risk of progression from SMM to MM
Federal Practitioner
Daratumumab regimen shows benefit in transplant-ineligible myeloma
Federal Practitioner
R2 appears active in high-risk FL and MZL
Federal Practitioner
Partners in Oncology Care: Coordinated Follicular Lymphoma Management (FULL)
Federal Practitioner
Cell count ratios appear to predict thromboembolism in lymphoma
Federal Practitioner
CNS-directed therapy appears more effective for synDLBCL
Federal Practitioner
R2-CHOP doesn’t improve survival in DLBCL
Federal Practitioner
SC daratumumab deemed feasible for every multiple myeloma patient
Federal Practitioner